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BACKGROUND: Malignant melanoma, generally described as incurable, is notoriously refractory to chemotherapy. The mechanisms
contributing to this have not yet been defined and the contributions of drug efflux pumps, implicated in chemo-resistance of many
other cancer types, have not been extensively investigated in melanoma.
METHODS: In this study, expression of multi-drug resistant (MDR1/P-gp and MRP-1) proteins was examined, by immunohistochemistry,
in archival specimens from 134 melanoma patients. This included 92 primary tumours and 42 metastases.
RESULTS: On assessing all specimens, MRP-1 and MDR1/P-gp expression was found to be common, with the majority (81%) of
melanomas expressing at least one of these efflux pumps. Although there is significant association between expression of these
pumps (P¼0.007), MRP-1 was found to be the predominant (67% of cases) form detected. w
2 analysis showed significant
associations between expression of MRP-1 and/or MDR1/P-gp and the aggressive nature of this disease specifically increased
Breslow’s depth, Clark’s level and spread to lymph nodes. This association with aggressiveness and spread is further supported by the
observation that a significantly higher percentage of metastases, than primary tumours, express MRP-1 (91% vs 57%; Po0.0001) and
MDR1/P-gp (74% vs 50%; P¼0.010).
CONCLUSION: The predominant expression of these pumps and, in particular, MRP-1 suggests that they may be important contributors
to the inherent aggressive and resistant nature of malignant melanoma.
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The incidence rate for cutaneous melanoma, which involves the
malignant proliferation of melanocytes, is increasing faster than
that of any other malignant disease, at an epidemic rate of 3% a
year (Leiter and Gerbe, 2008; Gerbe and Leiter, 2009). Over the last
century, melanoma has progressed from being considered as a rare
cancer to a situation in which the lifetime risk of developing this
disease is 1 in 50 in many Western populations (Giblin and
Thomas, 2007), with major socioeconomic consequences as a
result of the high mortality rates associated with this metastatic
disease (Meyle and Guldberg, 2009). Currently, approximately
133000 new cases of melanoma are diagnosed worldwide each
year. The NCI’s surveillance epidemiology and end results estimate
that in the United States, in 2009 alone, 68720 new cases of
melanoma of the skin will be diagnosed and 8650 people will die
from this disease.
Prognosis for patients with early-stage melanoma is very good
and can often be cured by wide surgical excision. Metastatic
disease, unfortunately, remains generally incurable and is largely
resistant to current therapies, with a median survival time of 6 to
9 months from the time of diagnosis and a 5-year survival rate of
5.5% (Keller et al, 2006; Sarnaik and Weber, 2009). Biological
therapies including IFN-a have shown a real, but minimal, effect in
malignant melanomas (Pavlick et al, 2003) and the effects of IL-2,
as a treatment for malignant melanoma, are not yet clearly defined.
High-dose bolus IL-2 produces some long-term remissions and is
available for highly selected individuals, but is not suitable for
most patients (Mohr et al, 2003; Agarwala, 2009). Chemo-
therapeutic therapy for melanoma has been attempted with the
many chemotherapeutic drugs. Single-agent chemotherapy, inclu-
ding dacarbazine, temozolomide, the nitrosoureas (BCNU, CCNU
and methyl CCNU), the vinca alkaloids (vincristine, vinblastine
and vindesine), cisplatin, paclitaxel and bleomycin, have been
used. Many of these are relatively well-tolerated (including
dacarbazine, which now has FDA approval for this indication),
but are associated with response rates of only 5–20% (Bhatia et al,
2009; Seetharamu et al, 2009). Multi-drug chemotherapy regimes
have resulted in objective response rates, but do not extend
survival and are associated with greater toxicity (Nystrom et al,
2003; Pawlik and Sondak, 2003; Tas et al, 2003; Bhatia et al, 2009).
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apparently due to the inherent drug refractory-nature of this
disease (Ichihashi and Kitajima, 2001; Colone et al, 2008). This has
resulted in targeted therapies being fast-tracked through FDA
approval, for example, Ipilimumab, which targets CTL4 and which
is approved for metastatic and advanced melanoma. Such
monoclonal antibodies are more expensive than traditional
chemotherapy and so are an economic burden on many health
systems. Unfortunately, they too may become of limited use
because of the resistance nature of melanoma.
There is some, albeit limited, evidence that expression of
genes encoding membrane efflux pumps (ABC transport proteins),
including MRP-1 (ABCC1) and multi-drug resistant 1(MDR1)/P-gp
(ABCB1), may be associated with this chemo-resistance and so with
the incurable nature of malignant melanomas. However, conflicting
data exists on the details of the specific pump(s) involved. In a study
of MRP-1 mRNA and protein expression in 40 melanoma cell lines,
Berger et al (1997) reported sensitivity to a broad range of chemo-
therapeutic drugs to inversely correlate with MRP-1 expression.
Furthermore, analysis of mrp-1 and mdr-1 mRNA expression in 18
specimens from eight melanoma patients’ tumours showed mrp-1
expression in the majority of pre-chemotherapy specimens, the levels
of which were increased post-chemotherapy. mdr-1 mRNA was,
however, not detected in any of the specimens analysed (Ichihashi
and Kitajima, 2001). In keeping with this, based on studies of 21
primary malignant melanomas and 37 metastases, Schadendorf et al
(1995) reported 43% of both primary and metastatic tumours to
express MRP-1, with a lack of detectable expression of MDR1/P-gp
(except in one primary tumour) suggesting that the chemo-resistant
nature of melanoma cells is unlikely to be mediated by MDR1/P-gp.
Conversely, results from studies of human melanoma cultured cells
(M14) suggested MDR1/P-gp, but not MRP-1, to be associated with
the MDR phenotype (Molinari et al, 2000). In further studies of M14
cell line variants (specifically, MDR1/P-gp-positive drug-resistant M14
ADR compared with MDR1/P-gp-negative drug sensitive M14 cells),
members of the same research group have more recently reported
M D R 1 / P - g pt ob el i n k e dw i t hM A P Ks i g n a l l i n ga n dt ob ei n v o l v e di n
melanoma cell migration and invasion (Colone et al, 2008).
As outlined above, although studies of melanoma cell line
models support an association between MDR1/P-gp and/or MRP-1
and the chemo-resistant, generally incurable, phenotype of
malignant melanoma, studies of the prevalence of MDR1/P-gp
and MRP-1 in melanoma specimens have been very limited and
conflicting. To determine the potential involvement of these drug
efflux pumps in the clinical setting, here we report results from
a retrospective study of both MDR1/P-gp and MRP-1 protein
expression and their associations with patients’ clinicopathological
features (where possible) in 134 melanomas, including 92 primary
tumours and 42 metastases.
MATERIALS AND METHODS
Patients
The patient group studied comprised 134 consenting patients with
malignant melanoma. All patients were diagnosed at St Vincent’s
University Hospital (SVUH), Dublin, between 1975 and 2002 and
approval to conduct this study was granted by the SVUH Ethics
Committee. Formalin-fixed paraffin-embedded material was avail-
able for all patients. Representative 4mm sections of tissue blocks
were cut using a microtome, mounted onto poly-l-lysine-coated
slides and dried overnight at 371C. Slides were stored at room
temperature until required.
Immunohistochemistry
All steps were performed at room temperature unless otherwise
indicated. Tissue sections were dewaxed in xylene (2 5min),
rehydrated in grading alcohols 100, 90 and 70% (2 3min each),
and placed in Tris Buffered Saline (TBS/0.05% Tween-20).
Endogenous Peroxidase activity was quenched by placing tissue
sections in 3% (v/v) H2O2/distilled water for 5-6min. All slides
were blocked for non-specific staining with 20% normal rabbit
serum (Dako, Glostrup, Denmark, X-902)TBS for 20min. Primary
antibodies were applied to each specimen. Specifically, anti-MDR1/
P-gp clone 6/1C ascites (which we developed and previously
extensively characterised as specific for MDR1P-gp; Moran et al,
1997) were diluted 1:40 in TBS/0.05% Tween-20. Anti-MRP-1
PA28(6) antibody, (which we similarly developed and extensively
characterised as specific for MRP-1; (Connolly et al, 2001)) was
applied as a neat supernatant. Primary antibodies were incubated
overnight at 41C. Samples were then washed (3 5min) with TBS/
0.05% Tween-20, followed by 30min incubation with biotinylated
secondary antibody diluted in TBS/0.05% Tween-20. Finally,
following another 3 5min. wash step, Vector SG substrate for
peroxidase (Vector Laboratories, Peterborough, UK, SK-4700) was
applied for approx. 10min. All slides were washed (3 5min.) in
TBS/0.05% Tween-20. Tissue sections were then lightly counter-
stained with nuclear fast red (Vector Laboratories, H-3403).
Following this, slides were dehydrated in 70, 90 and 100%
grading alcohols (2 3min.). Samples were then cleared in xylene
and mounted in DPX (BDH, London UK). Positive control, normal
kidney and lung tissue sections (using the same experimental
conditions), and negative control samples (in which the primary
antibody was replaced by 1  TBS/0.05% Tween-20) were included
in all experiments.
Immunohistochemical scoring
MRP-1 and MDR1/P-gp immunohistochemical staining was scored
(by the Consultant Pathologist, Prof. Susan Kennedy) according
Table 1 Clinicopathological features of patients studied for MDR1/P-gp
and MRP-1 expression in melanoma primary and metastatic specimens
Characteristics Primary (%) Metastatic (%)
Age (years)
o59 45.6 (42/92) 54.8 (23/42)
459 54.3 (50/92) 45.2 (19/42)
Gender
Male 32.6 (30/92) 50.0 (21/42)
Female 67.4 (62/92) 50.0 (21/42)
Lymph node spread
Negative 92.4 (85/92) 28.6 (12/42)
Positive 7.6 (7/92) 71.4 (30/42)
Clark’s level
I 1.08 (1/92) 97.6 (41/42)
II 10.9 (10/92) 0 (0/42)
III 32.3 (30/92) 0 (0/42)
IV 22.8 (21/92) 0 (0/42)
V 6.5 (6/92) 2.4 (1/42)
Unknown 26.1 (24/92) 0 (0/42)
Breslow thickness
o1mm 31.5 (29/92) 2.4 (1/42)
1–2mm 18.5 (17/92) 2.4 (1/42)
2.1–4mm 10.9 (10/92) 0 (0/42)
44mm 21.7 (20/92) 4.8 (2/42)
Unknown 17.4 (16/92) 90.5 (38/42)
Relapse
Relapse p5years 25.0 (23/92) 19.0 (8/42)
Did not Relapse p5years 14.1 (13/92) 7.1 (3/42)
Unknown 60.9 (56/92) 73.8 (31/42)
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sto the percentage of cells showing specific immunoreactivity.
A semi-quantitative measurement was used in which the overall
positivity of the tumour was assessed and a score of 1þ was given
if up to 25% of cells showed MRP-1 or MDR1/P-gp positive
staining, as relevant; a score of 2þ was given if X25–o50% cells
showed positive staining; a score of 3þ,i fX50–o75% of cells
showed positive staining; and a score of 4þ,i fX75% of
cells showed positive staining. Scores of 1 were considered as
negative; scores 4 1 were considered positive.
Statistical analysis
Statistical analyses of the results were performed using SPSS 16.0
and InStat software packages. Descriptive statistics were used to
summarise patient characteristics, and statistical analysis of the
results was performed using Pearson’s w
2 test to investigate
relationships between MDR1/P-gp and MRP-1 expression and
clinicopathological and histopathological findings. Kaplan–Meier
survival curves were established and were subsequently checked
using the log-rank, Breslow and Tarone-ware tests (P-values
represent log-rank, unless otherwise indicated) to assess the prog-
nostic significance of MDR1/P-gp and MRP-1 protein expression.
The data were analysed as a whole and as primary and metastases
cohorts, and, where relevant, the data were also censored at
5 years. A value of P o0.05 was considered to be statistically
significant.
RESULTS
Patient characteristics
This study involved analysis of tumours from 134 patients with
metastatic melanoma. Eighty-three of the patients were female;
51 were male. The patients’ age ranged between 22 and 104 years at
the time of diagnosis (median age¼59 years). A total of 92 of the
specimens available for analysis were primary tumours; 42 were
secondary metastases. Further clinical characteristics of the
patients are summarised in Table 1.
MDR1P-gp expression
MDR1/P-gp specific staining was observed in 57.5% (77 of 134) of
the melanoma specimens analysed (a representative MDR1/P-gp
Figure 1 Immunohistochemical analysis of MDR1/P-gp and MRP-1 protein expression. Representative melanoma specimens showing strongly positive
(4þ3) MDR1/P-gp (A) and MRP-1 (B) staining (4þ3). Images (C) and (D) show specimens that were negative for MDR1/P-gp and MRP-1 staining,
respectively. Image (E) represents negative control (scale bar¼100mm in all images; original magnifications of all photomicrographs  40).
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spositive tumour is shown in Figure 1A). Specific staining was
localised to cell membrane/cytoplasm. Approximately 43% of
tumours did not express MDR1/P-gp protein. MDR1/P-gp expres-
sion in primary and metastatic tumours, when analysed as separate
cohorts, was 50 and 73.8%, respectively.
MRP-1 expression
MRP-1-specific staining was observed in 67.2% (90 per 134) of
the tumours analysed ((Figure 1B) illustrates a typical example).
In all 33% of all tumours did not express MRP-1 protein.
Independent assessment of the primary tumours and metastases
indicated MRP-1 to be detected in 56.5 and 90.5% of cases,
respectively.
MDR1/P-gp and MRP-1 co-expression
The expressions of MDR1/P-gp and MRP-1 proteins were
significantly associated (P¼0.007). The majority (80.6%) of
melanomas expressed at least one of the efflux pumps analysed;
44% expressed both, while only 19.4% expressed neither MDR1/
P-gp nor MRP-1 proteins (see Table 2a). For the primary tumour
cohort alone, as summarised in Table 2b, approximately 73% of
cases expressed at least one of these pumps, 27% had neither
MDR1/P-gp nor MRP-1, while 34% expressed both proteins.
Table 2c indicates that the majority (97.6%) of the metastatic
specimens expressed MDR1/P-gp and/or MRP-1; 67% had both.
Almost a quarter (23.8%) of metastatic tumours had MRP-1, but
lacked MDR1/P-gp expression, whereas only 7% expressed MDR1/
P-gp alone.
Overall, as shown in Table 3, a direct comparison of MDR1/P-gp
and MRP-1 efflux pump expression in the primary vs meta-
static specimens indicated a significantly higher percentage
of metastatic tumours, when compared with primary tumours,
expressed MDR1/P-gp (primary 50%; metastases 74%;
P¼0.010) and MRP-1 (primary 57%; metastases 91%; Pp0.0001),
with MRP-1 being the most prevalent efflux pump in these
specimens.
MDR1/P-gp and MRP-1 expression in relation to
clinicopathological features
Using w
2 analysis of the 134 patients as a whole (summarised in
Table 4), MDR1/P-gp expression was found to be significantly
(P¼0.013) associated with lymph node positivity and tended to
be associated with increased Breslow’s depth; however, the latter
case, showed statistical significance (P¼0.052). MRP-1 expression
was also significantly associated with spread to the lymph nodes
(Po0.0005) and with more extensive invasion of the melanoma,
i.e., when comparing MRP-1 expression in specimens with
Clark’s level II, III and IV vs Clark’s level V; P¼0.032
(incidentally, comparison of MRP-1 expression in those specimens
with Clark’s levels II and III with that in specimens with Clark’s
levels IV and V also supported the association between MRP-1
expression and increasing stages of disease; (although NS,
P¼0.051)).
Assessing the expression of these efflux pumps in the cohort of
primary tumours alone (Table 5) showed similar trends to those
Table 2 Comparison of MDR1/P-gp and MRP-1 co-expression in (a) all
melanoma specimens analysed; (b) primary melanoma specimens only; and
(c) metastatic melanoma specimens only
Drug efflux pump % Cases
(a)
MRP1
+and MDR1/P-gp
+ 44.0 (59/134)
MRP1
  and MDR1/P-gp
+ 13.4 (18/134)
MRP1
+ and MDR1/P-gp
  23.1 (31/134)
MRP1
  and MDR1/P-gp
  19.4 (26/134)
(b)
MRP1
+ and MDR1/P-gp
+ 33.7 (31/92)
MRP1
  and MDR1/P-gp
+ 16.3 (15/92)
MRP1
+ and MDR1/P-gp
  22.8 (21/92)
MRP1
  and MDR1/P-gp
  27.2 (25/92)
(c)
MRP1
+ and MDR1/P-gp
+ 66.7 (28/42)
MRP1
  and MDR1/P-gp
+ 7.1 (3/42)
MRP1
+ and MDR1/P-gp
  23.8 (10/42)
MRP1
  and MDR1/P-gp
  2.4 (1/42)
Abbreviations: MDR1/P-gp¼multi-drug resistance; MRP¼multidrug resistance-
associated protein.
Table 3 Correlation between expression of MDR1/P-gp and MRP-1
protein in primary vs metastatic specimens
Tumour
site
No. of
cases
MDR
P-gp (%) P
No. of
cases
MRP-1
(%) P
Primary 46/92 50 0.010* 52/92 56.5 Po0.000*
Metastasis 31/42 73.8 38/42 90.5
Abbreviations: MDR1/P-gp¼multi-drug resistance; MRP¼multidrug resistance-
associated protein. P values from w
2 analyses; *indicates significant parameter.
Table 4 Correlation between clinicopathological factors and expression
of MDR1/P-gp and MRP-1 protein in all melanoma specimens analysed
Characteristics
No. of
cases
MDR
P-gp (%) P
No. of
cases
MRP-1
(%) P
Age (years)
o59 34/65 52.3 0.241 43/65 66.2 0.809
X59 43/69 62.3 47/69 68.1
Gender
Male 30/51 58.8 0.803 39/51 76.5 0.072
Female 47/83 56.6 51/83 61.4
Lymph node spread
Negative 50/98 51.0 0.013* 57/98 58.2 o0.0005*
Positive 27/36 75.0 33/36 91.7
Clark’s level
II and III 20/41 48.8 0.251 19/41 46.3 0.051
IV and V 17/27 63.0 19/27 70.3
Clark’s level
II, III, IV 32/62 51.6 0.136 32/62 51.6 0.032*
V 5/6 83.3 6/6 100
Breslow thickness
o1mm 14/30 46.7 0.052 13/30 43.3 0.107
1–4mm 11/28 39.3 16/28 57.1
44mm 16/22 72.7 11/22 50.0
Relapse
Relapse
within 5years
17/31 0.260 18/31 0.252
Abbreviations: MDR1/P-gp¼multi-drug resistance; MRP¼multidrug resistance-
associated protein. P values from w
2 analyses; *indicates significant parameter;
Clark’s score – information was available for 68 of 134 cases; Breslow’s thickness –
information was available for 80 of 134 cases.
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being associated with spread to the lymph nodes (P¼0.049) and
increasing Breslow’s depth (although NS, P¼0.056), with MRP-1
expression being significantly associated with increasing Clark’s
level (P¼0.023).
In relation to the metastases cohort alone, as the majority of
these specimens expressed MRP-1 (B91%) and MDR1/P-gp
(B74%), seeking association with clinicopathological factors is
not relevant here.
DISCUSSION
Malignant melanoma is one of the most challenging cancers to
treat, resulting in highest per-death loss of years of potential life
expectancy with the exception of adult leukaemia (Seetharamu et al,
2009). Unfortunately, the effectiveness of chemotherapeutic regimes
evaluated in this cancer type is compromised and very limited,
owing to the yet undefined highly resistant nature of this cancer.
Drug efflux pumps, MDR1/P-gp and MRP-1, have been asso-
ciated with chemo-resistance in a number of cancer types. Studies
of drug efflux pumps in melanoma have, however, been very
limited to date. As outlined previously, studies of melanoma cell
line models have resulted in conflicting results, some suggesting a
role for MRP-1 (Berger et al, 1997), while others propose
MDR1/P-gp to be potentially of more relevance (Molinari et al,
2000; Colone et al, 2008). Both earlier studies of melanoma
tissue specimens (from 8 and 58 patients, evaluating mRNAs
and proteins, respectively) reported MRP-1, but generally not
MDR P-gp, expression (Schadendorf et al, 1995; Ichihashi and
Kitajima, 2001). Although those studies were important in
highlighting the potential relevance of a drug efflux pump (namely,
MRP-1) in melanoma, the numbers of specimens included were
very limited. Furthermore, associations with patients’ clinical
characteristics were not investigated.
Here, in this more extensive study of 134 melanoma specimens,
in agreement with the studies by Schadendorf et al (1995), we
report MRP-1 protein to be typically expressed in melanoma.
However, whereas Schadendorf et al (1995) reported the pre-
valence of expression to be the same in primary tumours and
metastases, we observed that significantly higher percentages
of metastatic specimens, compared with primary tumours,
express MRP-1. Furthermore, in contrast to the work reported
by Schadendorf et al (1995) in which MDR1/P-gp was detected
in only 1 of 21 primary specimens and was absent from metastases,
we detected MDR1/P-gp in more than half of the specimens
analysed. As for MRP-1, expression of MDR1/P-gp was signi-
ficantly more frequent in metastases compared with primary
tumours. The discrepancies between our work and that reported
by Schadendorf et al (1995) may, at least partly, be related to the
larger cohort of specimens to which we had access in our analysis.
We propose that such large studies could potentially contribute
to more clinically relevant results.
This, we believe, is the first study evaluating potential asso-
ciations between MDR1/P-gp and/or MRP-1 expression and mela-
noma patients’ clinicopathological characteristics. Although we
found no significant association between either the presence of
either efflux pump or the age and gender of the patients, we
identified that expression of these pumps tended to be associated
with the more aggressive nature of melanoma. Specifically, MRP-1
expression was significantly associated with tumours classified
as having a Clark’s level of V (i.e., invading the subcutaneous fat,
instead of being limited to the epidermal or dermal layers of the
skin). Although statistical significance was not reached, MDR1/
P-gp expression tended to be more strongly associated with
tumours having a staging Breslow’s thickness of 44mm which,
according to the AJCC guidelines, is prognostic of a 5-year.
survival of approximately 50% (compared with 95–100% for
o1mm; 80–95% for 1–2mm; and 60–80% for 2.1–4mm).
Furthermore, we established that both MRP-1 and MDR1/P-gp
expression are significantly associated with spread of cancer to
the lymph nodes. The observed associations between expression
of these efflux pumps and the more aggressive phenotype of
melanoma, together with the significantly higher prevalence of
these pumps (MRP-1, in particular) in metastases compared with
primary specimens, suggests that MRP-1 and MDR1/P-gp may
contribute, at least to some extent, to the incurable nature of
malignant melanoma.
In conclusion, this study indicates that expression of drug efflux
pumps, MRP-1 and MDR1/P-gp, is common in melanoma,
especially in metastases, and so potentially could contribute to
the chemo-resistant biology and thus incurable nature of this
cancer type. The expression of these proteins – and, in particular,
the predominant expression of MRP-1 – suggests that these pumps
may be important contributors to this chemo-resistance. These
findings suggest that the inhibition of multiple drug efflux pumps
might be necessary if clinically relevant MDR reversal is to be
achieved in malignant melanoma.
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Table 5 Correlation between clinicopathological factors and expression
of MDR1/P-gp and MRP-1 protein in primary tumours only
Characteristics
No. of
cases
MDR
P-gp (%) P
No. of
cases
MRP-1
(%) P
Age (years)
o59 19/42 45.2 0.402 22/42 52.4 0.463
X59 27/50 54.0 30/50 60.0
Gender
Male 14/30 46.7 0.656 21/30 70.0 0.070
Female 32/62 51.6 31/62 50.0
Lymph node spread
Negative 40/85 47.1 0.049* 46/85 54.1 0.105
Positive 6/7 85.7 6/7 85.7
Clark’s level
II and III 20/41 48.8 0.251 19/41 46.3 0.051
IV and V 17/27 63.0 19/27 70.3
Clark’s level
II, III, IV 32/62 51.6 0.136 32/62 51.6 0.023*
V 5/6 83.3 6/6 100.0
Breslow thickness
and lt;1mm 14/29 48.3 0.056 12/29 41.4 0.139
1–4mm 11/27 40.7 15/27 55.6
44mm 15/20 75.0 14/20 70.0
Relapse
Relapse
within 5years
11/23 47.8 0.587 10/23 43.5 0.137
Abbreviations: MDR1/P-gp¼multi-drug resistance; MRP¼multidrug resistance-
associated protein. P values from w
2 analyses; *indicates significant parameter;
Clark’s score – information was available for 68 of 92 cases; Breslow’s thickness –
information was available for 76 of 92 cases; relapse information available for 36
cases.
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